Univariate analysis of 5-year OS from diagnosis and EFS from HSCT
Patient group . | OS from diagnosis, % (95% CI) . | N . | Events . | P . | EFS from HSCT, % (95% CI) . | N . | Events . | P . |
---|---|---|---|---|---|---|---|---|
Entire cohort | 45 (33-57) | 82 | 42* | 41 (29-53) | 77 | 44† | ||
LIN28B | ||||||||
High | 27 (9-45) | 42 | 25 | .03 | 21 (3-39) | 40 | 27 | .02 |
Low | 60 (44-76) | 40 | 17 | 56 (43-69) | 37 | 17 | ||
Age at diagnosis, y | ||||||||
<2 | 58 (41-75) | 42 | 16 | .01 | 58 (42-74) | 40 | 17 | <.01 |
≥2 | 32 (15-49) | 40 | 26 | 20 (1-39) | 37 | 27 | ||
HbF | ||||||||
Normal | 68 (45-91) | 16 | 5 | NS | 71 (47-95) | 14 | 4 | .05 |
Elevated | 45 (30-60) | 55 | 29 | 37 (23-51) | 53 | 33 | ||
Karyotype | ||||||||
Normal | 55 (40-70) | 54 | 24 | .07 | 48 (33-63) | 52 | 27 | NS |
Monosomy 7 | 33 (7-59) | 17 | 10 | 30 (5-55) | 15 | 10 | ||
Other | 0 | 8 | 6 | 0 | 7 | 5 | ||
Molecular genetics | ||||||||
PTPN11 | 34 (15-53) | 36 | 21 | .04 | 26 (9-43) | 36 | 25 | .01 |
KRAS | 65 (40-90) | 15 | 5 | 75 (50-100) | 12 | 3 | ||
NRAS | 64 (38-90) | 15 | 5 | 63 (36-90) | 14 | 5 | ||
NF1 | 0 | 5 | 5 | 0 | 4 | 4 | ||
Quadruple negative | 53 (22-84) | 11 | 6 | 36 (7-65) | 11 | 7 |
Patient group . | OS from diagnosis, % (95% CI) . | N . | Events . | P . | EFS from HSCT, % (95% CI) . | N . | Events . | P . |
---|---|---|---|---|---|---|---|---|
Entire cohort | 45 (33-57) | 82 | 42* | 41 (29-53) | 77 | 44† | ||
LIN28B | ||||||||
High | 27 (9-45) | 42 | 25 | .03 | 21 (3-39) | 40 | 27 | .02 |
Low | 60 (44-76) | 40 | 17 | 56 (43-69) | 37 | 17 | ||
Age at diagnosis, y | ||||||||
<2 | 58 (41-75) | 42 | 16 | .01 | 58 (42-74) | 40 | 17 | <.01 |
≥2 | 32 (15-49) | 40 | 26 | 20 (1-39) | 37 | 27 | ||
HbF | ||||||||
Normal | 68 (45-91) | 16 | 5 | NS | 71 (47-95) | 14 | 4 | .05 |
Elevated | 45 (30-60) | 55 | 29 | 37 (23-51) | 53 | 33 | ||
Karyotype | ||||||||
Normal | 55 (40-70) | 54 | 24 | .07 | 48 (33-63) | 52 | 27 | NS |
Monosomy 7 | 33 (7-59) | 17 | 10 | 30 (5-55) | 15 | 10 | ||
Other | 0 | 8 | 6 | 0 | 7 | 5 | ||
Molecular genetics | ||||||||
PTPN11 | 34 (15-53) | 36 | 21 | .04 | 26 (9-43) | 36 | 25 | .01 |
KRAS | 65 (40-90) | 15 | 5 | 75 (50-100) | 12 | 3 | ||
NRAS | 64 (38-90) | 15 | 5 | 63 (36-90) | 14 | 5 | ||
NF1 | 0 | 5 | 5 | 0 | 4 | 4 | ||
Quadruple negative | 53 (22-84) | 11 | 6 | 36 (7-65) | 11 | 7 |